......if GERN visited the $0.80s.....maybe, even, $0.70s. Management doesn't seem to have a plan. The "street" appears to have no confidence in the company. Geron doesn't want to spend money on r&d on its own any more. Management gives the impression it knows Imetelstat for use in blood disorders is the last card in its deck......which gives it, at best, a "Imetelstat, high" hand
Maybe this "idiot" thinks it would be even more idiotic to sell now........and take a $200,000 loss (which, as I keep telling the multiple-ID, "fringe-lunatic", Geron-negative, Bozo calling itself "wereinayellowsubmarine" (today, at least) hasn't happened yet)).....when Imetelstat still has a chance to be a breakthrough drug.